Anti-CD117-SAP References

Cat. #IT-83

2021

Skulimowska I, Sosniak J, Gonka M, Szade A, Jozkowicz A, Szade K (2021) The biology of hematopoietic stem cells and its clinical implications. FEBS J 16192. doi: 10.1111/febs.16192

Objective: To review the opportunities and challenges of recent findings to improve the clinical use of hematopoietic stem cells (HSCs)
Summary: The authors describe new methods of HSC mobilization and conditioning for transplantation and highlight research that may lead to solutions for the limitations of HSC transplantation
Dose: See (Palchaudhuri, R., 2016, https://atsbio.com/tt16q3-article1/)

2019

Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, & Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. (2019) Nat Commun 10:617. doi: 10.1038/s41467-018-08201-x

Objective:  To investigate a safe and effective method for hematopoietic stem cell transplantation.
Summary:  CD117-ADC selectively targets hematopoietic stem cells yet does not cause clinically significant side-effects.
Dose:  The CD117-ADC was prepared by combining biotinylated anti-CD117 (clone 2B8) with Streptavidin–ZAP.  A dose of 1.5 mg/kg of CD117-ADC (~12 µg Streptavidin-ZAP) optimally resulted in depletion of >99% of immunophenotypic and functional HSCs.